Literature DB >> 28093814

Management of sickle cell disease in patients undergoing cardiac surgery.

Todd C Crawford1, Michael V Carter1, Rina K Patel2, Alejandro Suarez-Pierre1, Sophie Z Lin1, Jonathan Trent Magruder1, Joshua C Grimm1, Duke E Cameron1, William A Baumgartner1, Kaushik Mandal1.   

Abstract

Sickle cell disease is a life-limiting inherited hemoglobinopathy that poses inherent risk for surgical complications following cardiac operations. In this review, we discuss preoperative considerations, intraoperative decision-making, and postoperative strategies to optimize the care of a patient with sickle cell disease undergoing cardiac surgery.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh：

Year:  2017        PMID： 28093814     DOI： 10.1111/jocs.13093

Source DB:  PubMed          Journal:  J Card Surg        ISSN： 0886-0440            Impact factor:   1.620


  4 in total

Review 1.  Optimizing management of sickle cell disease in patients undergoing surgery.

Authors:  Charity I Oyedeji; Ian J Welsby
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Axillary intra-aortic balloon pump, biventricular assist device implantation and subsequent orthotopic heart transplantation in a patient with sickle cell trait.

Authors:  Marcus Taylor; Zakariya Mouyer; Paul Callan; Steve Shaw; Rajamiyer Venkateswaran; Nnamdi Nwaejike
Journal:  J Surg Case Rep       Date:  2022-06-18

3.  Spontaneous splenic rupture, mesenteric ischemia and spinal infarction after aortic repair for acute type A dissection in a patient with sickle cell trait.

Authors:  Makoto Toyoda; Tadashi Kitamura; Kouki Nakashima; Yoshikiyo Matsunaga; Masaki Nie; Kagami Miyaji
Journal:  Gen Thorac Cardiovasc Surg       Date:  2020-10-22

4.  Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension and hemoglobinopathies.

Authors:  Ana Cecília Cardoso de Sousa; Frederico Thadeu Assis Figueiredo Campos; Rodrigo de Castro Bernardes; Marcelo Braga Ivo; Ricardo de Amorim Corrêa
Journal:  J Bras Pneumol       Date:  2020-03-27       Impact factor: 2.800
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.